Patent Strategy in Pharmaceutical Industry: Are additional patents valuable? (Record no. 65231)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02160naaaa2200277uu 4500 |
| 001 - CONTROL NUMBER | |
| control field | https://directory.doabooks.org/handle/20.500.12854/55772 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20220220043118.0 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | /dx.doi.org/10.5771/9783845251288 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9783845251288 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | http://dx.doi.org/10.5771/9783845251288 |
| Terms of availability | doi |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | English |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Donghi, Monica |
| Relationship | auth |
| 245 10 - TITLE STATEMENT | |
| Title | Patent Strategy in Pharmaceutical Industry: Are additional patents valuable? |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Nomos Verlagsgesellschaft mbH & Co. KG |
| Date of publication, distribution, etc. | 2014 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 electronic resource (84 p.) |
| 506 0# - RESTRICTIONS ON ACCESS NOTE | |
| Terms governing access | Open Access |
| Source of term | star |
| Standardized terminology for access restriction | Unrestricted online access |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | This book investigates lifecycle management strategies used by pharmaceutical companies attempting to maximize the value of their product portfolio. Such strategies are sometimes referred to by generic drug companies as “evergreening”. The analysis focuses on two of these strategies, namely product improvements and product line extensions. In particular, an evaluation of the patents that follow the basic one and that accompany the development of a drug from research to market is attempted. Two “blockbuster” drugs, Taxotere and Xalatan, were randomly chosen to carry out such analysis. The patent portfolio of the originator companies is outlined and some important patents for each area of research (e.g. formulations, combinations, delivery devices) are shortly described. Patent filing trends for the two drugs, both in regards of the originator and in regards of other competing companies (amongst these also the generics) are schematically shown. |
| 540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE | |
| Terms governing use and reproduction | Creative Commons |
| Use and reproduction rights | https://creativecommons.org/licenses/by/4.0/ |
| Source of term | cc |
| -- | https://creativecommons.org/licenses/by/4.0/ |
| 546 ## - LANGUAGE NOTE | |
| Language note | English |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Markenrecht |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Gewerblicher Rechtsschutz |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Host name | www.oapen.org |
| Uniform Resource Identifier | <a href="https://www.nomos-elibrary.de/10.5771/9783845251288">https://www.nomos-elibrary.de/10.5771/9783845251288</a> |
| Access status | 0 |
| Public note | DOAB: download the publication |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Host name | www.oapen.org |
| Uniform Resource Identifier | <a href="https://directory.doabooks.org/handle/20.500.12854/55772">https://directory.doabooks.org/handle/20.500.12854/55772</a> |
| Access status | 0 |
| Public note | DOAB: description of the publication |
No items available.